Elephant herpesvirus vaccine shows early promise in Houston

At Baylor College of Medicine in Houston, researchers say an experimental elephant herpesvirus vaccine has shown its first signs of protection against a virus that kills young Asian elephants. The early finding matters because elephant endotheliotropic herpesvirus, or EEHV, has become one of the leading causes of death in captive elephant calves.

The work comes from a Houston-based research team studying a disease that has challenged zoos and conservation programs for years. EEHV can move fast, often causing severe bleeding and organ damage in calves before treatment can work. That has left researchers searching for a preventive tool rather than relying only on emergency care after symptoms appear.

Elephant herpesvirus vaccine prompted an immune response

According to Baylor College of Medicine, the vaccine produced an immune response in elephants, a sign that it may help the animals recognize and fight the virus. The report described this as an early step, not final proof that the vaccine prevents disease in every case. Researchers are still working to understand how strong that protection is and how long it lasts.

The virus does not pose the same threat to people, but it has had an outsized effect on elephant populations under human care. Asian elephants are already endangered, and the loss of calves can affect breeding programs across multiple institutions. A vaccine that lowers the risk of fatal illness could give zoos and conservation groups another option to protect young elephants during their most vulnerable months.

Houston research could aid zoos and conservation programs

Baylor’s update points to a broader goal than one lab result. Scientists want a vaccine that can be used safely in elephants at zoos and wildlife facilities where EEHV remains a constant concern. An effective shot could help veterinarians intervene before calves become critically ill, which is a major shift from the current pattern of rapid response after infection takes hold.

The report did not present the project as finished. More study is needed before the vaccine can be used widely, including additional work on dosing, protection levels and real-world use in elephant care settings. Still, the first evidence of immune protection marks a notable milestone for a disease with few reliable defenses.

Researchers will continue evaluating the vaccine as they gather more data on safety and effectiveness. Baylor College of Medicine shared the findings this week through its blog network, where the team outlined the next stages of testing and the need for continued study.

This article is a summary of reporting by Baylor College of Medicine Blog Network. Read the full story here.